Related Experiment Video
Updated: Jun 24, 2026
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Glucagon-like Peptide-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: Insights From a Pilot
Gerges Mirna1, Nichols Carly1, MacDuff Kenzie1
1Division of Respirology, Department of Medicine, Nova Scotia Health, Halifax, Nova Scotia, Canada.
Canadian Journal of Diabetes
|June 22, 2026
Summary
Injectable semaglutide shows promise for managing cystic fibrosis-related diabetes (CFRD) in adults. This pilot study highlights the importance of careful patient selection and monitoring for effective glycemic control in this unique population.
Area of Science:
- Endocrinology
- Pulmonology
- Metabolic disorders
Background:
- Cystic fibrosis-related diabetes (CFRD) management is shifting due to rising overweight/obesity rates in the CF population.
- Widespread use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators impacts CFRD prevalence and management strategies.
Purpose of the Study:
- To evaluate the practical implementation of injectable semaglutide, a GLP-1 receptor agonist (GLP-1 RA), in adults with CFRD.
- To identify key considerations for patient selection, monitoring, and adverse event management for GLP-1 RA therapy in CFRD.
Main Methods:
- A pilot program involving 11 adult participants with CFRD over a 12-month period.
- Assessment of patient tolerance, glycemic control, and adverse effects during semaglutide treatment.
Main Results:
- Most participants tolerated semaglutide well, achieving clinically meaningful improvements in glycemic control.
- Careful patient screening and close clinical follow-up were essential for successful implementation.
- GLP-1 RA therapy demonstrated potential as an adjunct to insulin in selected CFRD patients.
Conclusions:
- Injectable semaglutide offers a viable therapeutic option for select adults with CFRD.
- The findings provide practical guidance for clinicians considering GLP-1 RA therapy in this specialized patient group.
- Further research is warranted to optimize GLP-1 RA use in CFRD management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...